CTT Pharmaceutical Holdings Advances Patent Portfolio in Europe and U.S.

CTT Pharmaceutical Holdings, Inc. announced that it has received an intention to grant from the European Patent Office (EPO) for additional claims to its original European patent. The company previously received approval for its micelle delivery system but decided to further refine the patent, particularly for diabetes-related medications.

With the expiration of the patent for the diabetes drug Liraglutide, CTT Pharma plans to explore the use of its micelle technology for this drug. The company believes this technology could enhance the drug delivery systems of currently patented diabetes medications and those in development.

CTT Pharma is also focused on strengthening its patent holdings in both Europe and the United States. The company aims to file new provisional patents throughout 2025 to safeguard its technological advancements.